A real-world analysis of Oregon’s regulated nonmedical psilocybin program reported broadly favorable experiences and a low rate of serious adverse reactions. The study, led by Todd Korthuis at Oregon Health & Science University, analyzed outcomes in nearly 350 participants who received psilocybin at state-licensed centers and published in JAMA Network Open. Investigators reported that most participants described their trip as beneficial, with more than half ranking it among the most meaningful experiences of their lives. The researchers also said overall safety appeared consistent with typical psychiatric interventions, noting only a small number of participants experienced serious adverse reactions. While not a traditional FDA drug-development trial, the dataset provides additional evidence relevant to how regulated settings handle dosing, monitoring, and participant support—factors that often matter in later approval-directed studies. The results arrive as multiple groups pursue formal clinical trials for psilocybin in mental health indications, supported by earlier human data using synthetic psilocybin.